Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mookerjee

Showing results (431-440 of 461) with videos related to

Pageof 47
Sort By:
ERJ Open Research|February 9, 2022
Physiological effects and subjective tolerability of prone positioning in COVID-19 and healthy hypoxic challengeAkhilesh Jha, Fangyue Chen, Sam Mann, et al.
Journal of Hepatology|September 8, 2020
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope ConsortiumElsa Solà, Elisa Pose, Daniela Campion, et al.
The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
Journal of Hepatology|June 21, 2014
Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failureRajiv Jalan, Faouzi Saliba, Marco Pavesi, et al.
JHEP Reports : Innovation in Hepatology|February 18, 2026
Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosisSven Lamatsch, Mohsin Hassan, Kai Kappert, et al.
Nature|June 5, 2020
Mouse models of neutropenia reveal progenitor-stage-specific defectsDavid E Muench, Andre Olsson, Kyle Ferchen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Cancer Discovery|February 13, 2018
Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal CancerRyan B Corcoran, Thierry André, Chloe E Atreya, et al.
Bone Marrow Transplantation|February 10, 2004
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphomaG L Phillips, B R Meisenberg, D E Reece, et al.
Blood|January 20, 2022
CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemiaCavan Bennett, Moyra Lawrence, Jose A Guerrero, et al.
Pageof 47

Showing results (431-440 of 461) with videos related to

Sort By:
Pageof 47
ERJ Open Research|February 9, 2022
Physiological effects and subjective tolerability of prone positioning in COVID-19 and healthy hypoxic challengeAkhilesh Jha, Fangyue Chen, Sam Mann, et al.
Journal of Hepatology|September 8, 2020
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope ConsortiumElsa Solà, Elisa Pose, Daniela Campion, et al.
The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
Journal of Hepatology|June 21, 2014
Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failureRajiv Jalan, Faouzi Saliba, Marco Pavesi, et al.
JHEP Reports : Innovation in Hepatology|February 18, 2026
Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosisSven Lamatsch, Mohsin Hassan, Kai Kappert, et al.
Nature|June 5, 2020
Mouse models of neutropenia reveal progenitor-stage-specific defectsDavid E Muench, Andre Olsson, Kyle Ferchen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Cancer Discovery|February 13, 2018
Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal CancerRyan B Corcoran, Thierry André, Chloe E Atreya, et al.
Bone Marrow Transplantation|February 10, 2004
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphomaG L Phillips, B R Meisenberg, D E Reece, et al.
Blood|January 20, 2022
CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemiaCavan Bennett, Moyra Lawrence, Jose A Guerrero, et al.
Pageof 47